Gene · 100288687
Papers1,532
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,532
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Nanopore Ultra-Long Sequencing for FSHD: From Molecular Diagnosis to Preimplantation Genetic Testing. | Genes (Basel) | 2026 | 42792998 | PubTator, text mining | PubMed |
| Undifferentiated round cell sarcoma with CIC::NUTM1 fusion: expanding the clinicopathologic spectrum of a rare molecular variant of CIC-rearranged sarcoma. | Virchows Arch | 2026 | 42693277 | PubTator, text mining | PubMed |
| EARLY RESPONSE AND GENETICS DEFINE RELAPSE RISK AFTER FRONTLINE BLINATUMOMAB IN CHILDHOOD B-ALL: A COHORT STUDY. | Blood Adv | 2026 | 42679210 | PubTator, text mining | PubMed |
| Biomarkers in facioscapulohumeral muscular dystrophy. | Curr Opin Neurol | 2026 | 42630082 | PubTator, text mining | PubMed |
| Cup-Like Nuclei Is a Hallmark of DUX4/ERG Acute Lymphoblastic Leukemia and Reveals Cytoplasmic Mitochondria Accumulation. | Pediatr Blood Cancer | 2026 | 42520297 | PubTator, text mining | PubMed |
| Personalized reference genome-based pipeline reveals comprehensive haplotype-resolved views of cancer genomes. | bioRxiv | 2026 | 42465473 | PubTator, text mining | PubMed |
| MYH2 as a Potential Modifier of Clinical Severity in Facioscapulohumeral Muscular Dystrophy. | J Mol Neurosci | 2026 | 42390820 | PubTator, text mining | PubMed |
| Cytological Features of CIC-Rearranged Sarcoma: A Report of 5 New Cases and Review of the Literature. | Acta Cytol | 2026 | 42378138 | PubTator, text mining | PubMed |
| Identification of compounds that repress DUX4 expression in facioscapulohumeral muscular dystrophy. | Sci Rep | 2026 | 42304059 | PubTator, text mining | PubMed |
| Targeting CIC::DUX4 sarcoma with Minnelide in a dual recombinase-initiated genetically engineered mouse model. | J Clin Invest | 2026 | 42302177 | PubTator, text mining | PubMed |
| Nanoparticle therapeutics in FSHD: current research and future perspectives. | Nanoscale | 2026 | 42301101 | PubTator, text mining | PubMed |
| CIC-DUX4 Rearranged Gastric Sarcoma Confirmed by Next-Generation Sequencing: A Case Report and Review of Literature. | Clin Case Rep | 2026 | 42256952 | PubTator, text mining | PubMed |
| The emergence and diversification of the DUX gene family across placental mammals. | Commun Biol | 2026 | 42249080 | PubTator, text mining | PubMed |
| Elevated labile iron contributes to membrane repair deficits in facioscapulohumeral muscular dystrophy. | iScience | 2026 | 42181289 | PubTator, text mining | PubMed |
| Mechanisms coordinating exit from the stem cell state in mammals. | Genes Dev | 2026 | 42156139 | PubTator, text mining | PubMed |
| Genomic profiling of a DICER1-wildtype thyroblastoma reveals AGK-BRAF fusion, EIF1AX duplication, and TERT promoter mutations: integrated genomic and pathway analysis. | Front Endocrinol (Lausanne) | 2026 | 42100208 | PubTator, text mining | PubMed |
| Spatiotemporal DUX4 toxicity in FSHD: from epigenetic derepression to biomarker-driven targeted therapies. | Neuromuscul Disord | 2026 | 42066431 | PubTator, text mining | PubMed |
| IntegrateALL: An end-to-end RNA-seq analysis pipeline for multilevel data extraction and interpretable subtype classification in B-precursor ALL. | Hemasphere | 2026 | 42007446 | PubTator, text mining | PubMed |
| Development of a DUX4-targeting antibody oligonucleotide conjugate as a therapy for FSHD. | Nucleic Acids Res | 2026 | 41994867 | PubTator, text mining | PubMed |
| KLF18 is a necessary component of the DUX4-initiated transcriptional network and a candidate locus for phenotypic diversity. | Genes Dev | 2026 | 41986233 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/100288687/papers